Nature Biotechnology 2006 - Abstracts
| Nature Biotechnology 2006 | |||||
| Title | Subject | Authors | |||
|---|---|---|---|---|---|
| AAV does the shuffle.(deno-associated virus) | Business | R. Jude Samulski, Aarvind Asokan | |||
| AAV hits the genomic bull's-eye: Adeno-associated virus mediates correction of genetic mutations in mouse liver.(adeno-associated Virus) | Business | John F. Engelhardt | |||
| Abe Abuchowski. | Business | Alla Katnelson | |||
| A change in the market - investing in diagnostics. | Business | Peter Miller, Keith Batchelder | |||
| A consensus epitope prediction approach identifies the breadth of murine [T.sub.CD8+]-cell responses to vaccinia virus. | Business | Alessandro Sette, David C. Tscharke, Magdalini Moutaftsi, Bjoern Peters, Valerie Pasquetto, John Sidney, Huynh-Hoa Bui, Howard Grey | |||
| Activism unleashed and unconscionable. | Business | Henry I. Miller | |||
| A fluorescent variant of a protein from the stony coral Montipora facilitates dual-color single-laser fluorescence cross-correlation spectroscopy. | Business | Atsushi Miyawaki, Masataka Kinjo, Takako Kogure, Satoshi Karasawa, Toshio Araki, Kenta Saito | |||
| A framework for the use of genomics data at the EPA. | Business | David J. Dix, Kathryn Gallagher, William H. Benson, Brenda L. Groskinsky, J. Thomas McClintock, Kerry L Dearfield, William H. Farland | |||
| A genetically encoded photosensitizer. | Business | Konstantin A. Lukyanov, Dmitriy M. Chudakov, Sergey Lukyanov, Tatyana V. Chepurnykh, Maria E. Bulina, Ekaterina M. Merzlyak, Olga V. Britanova, Yurii G. Yanushevic, Dmitry Staroverov B., Maria A. Shkrob | |||
| A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. | Business | Michel Sadelain, Isabelle Riviere, Ping Zhu, Selda Samakoglu, Rosalba Di Marzo, Aurelio Maggio, John F. Tisdale, Tulin Budak-Alpdogan, Yelena Usachenko, Santina Acuto | |||
| Aligning career ladders and the company vision. | Business | Jennifer A. Troia | |||
| A liposome-PCR assay for the ultrasensitive detection of biological toxins.(polymerase chain reaction) | Business | Jeffrey T. Mason, Lixin Xu, Zong-mei Sheng, Timothy J. O'Leary | |||
| All in the RNA family: Small interfering RNA is targeted to a specific cell type in vivo using an RNA aptamer. | Business | Beverly L. Davidson | |||
| A luxRury of synthetic signals. | Business | Stephen W. Michnick | |||
| A microengraving method for rapid selection of single cells producing antigen-specific antibodies. | Business | Hidde L. Ploegh, J. Christopher Love, Jehnnna L. Ronan, Gijsbert M. Grotenberg, Annemarthe G. van der Veen | |||
| A micropunch against plant viruses. | Business | Juan Antonio Garcia, Carmen Simon-Mateo | |||
| A milestone for endophyte biotechnology. | Business | Kiwamu Minamisawa | |||
| Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. | Business | Andreas W.M. Dress, Walter Schubert, Bernd Bonnekoh, Marcus Bode, Ansgar J. Pommer, Manuela Friedenberger, Lars Philipsen, Harald Gollnick, Raik Bockelmann, Yanina Malykh | |||
| An essential role for Akt1 in dendritic cell function and tumor immunotherapy. | Business | Kevin M. Slawin, David M. Spencer, Dongsu Park, Natalia Lapteva, Mamatha Seethammagari | |||
| A new lease on life for dendritic cell vaccines? | Business | Frank O. Nestle | |||
| An explosive-degraded cytochrome P450 activity and its targeted application for the phytoremediation of RDX. | Business | Neil C. Bruce, Stuart E. Strand, Elizabeth L. Rylott, Deborah Ratgbone, Rosamond G. Jackson, James Edward, Grant L. Womack, Helena MB Seth-Smith | |||
| An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly. | Business | Stephen J. Stray, Jennifer M. Johnson, Benjamin G. Kopek, Adam Zlotnick | |||
| Anthony Atala.(human trial of tissue-engineered bladders) | Business | Kathy Aschheim | |||
| Antibacterial discovery and development-the failure or success? | Business | Prabhavathi Fernandes | |||
| Antibiotics-an investment worth making? | Business | Ralph E. Christoffersen | |||
| Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. | Business | Robert E.W. Hancock, Hans-Georg Sahl | |||
| A passion for collaboration from the get-go: Merk and Co., Inc. and Bioxell show how big pharma and small biotechs can make perfect partners.(partnership of Merck and Company Inc. and BioXell SpA) | Business | ||||
| A peptide chaperone for transdermal drug delivery. | Business | Mark R. Prausnitz | |||
| A probability-based approach for high-throughput protein phosphorylation analysis and site localization. | Business | Steven P. Gygi, Scott A. Gerber, John Rush, Judit Villen, Sean A. Beausoleil | |||
| A regulatory perspective on in vitro diagnostics.(Food and Drug Administration) | Business | Scott Gottlieb, Janet Woodcock | |||
| Are we stuck in the standards? | Business | Catherine A. Ball | |||
| Artificial sperm and epigenetic reprogramming. | Business | Wolf Reik, Diabna Lucifero | |||
| A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. | Business | George M. Church, Mason W. Freeman, Claudio Punzo, Winston Patrick Kuo, Mark E. Whipple, Tor-Kristian Jenssen, Lucila Ohno-Machado, Brian Seed, Fang Liu, Jeff Trimarchi, Michael Lombardi, Jasjit Sarang, Malini Maysuria, Kyle Serikawa, Sun Young Lee, Donald McCrann, Jason Kang, Jeffrey R. Shearstone, Jocelyn Burke, Daniel J. Park, Xiaowei Wang, Trent L. Rector, Ricciardi-Castagnoli Paola, Steven Perrin, Sangdun Choi, Roger Bumgarner, Ju Han Kim, Glenn F. Short, Roderick Jensen, Eivind Hoving, Connie L. Cepko, Peter Park | |||
| A SLAMS dunk for cancer regulators. | Business | Arul M. Chinnaiyan, Chandan Kumar-Sinha | |||
| A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. | Business | Bryan R.G. Williams, Takashi Fujita, Mark A. Behlke, Joao Trindade Marques, Thalie Devosse, Die Wang, Maryam Zamanian-Daryoush, Paul Serbinowski, Rune Hartmann | |||
| A sugar switch for anti-inflammatory antibodies. | Business | Roy Jefferis | |||
| Automated phosphorylation site mapping. | Business | Ole N. Jensen | |||
| Bayh-Dole: If we knew then what we know now. | Business | Sara Boettinger, Alan B. Bennett | |||
| Big pharma wants you. | Business | George S. Mack | |||
| Biogenerics at the crossroads.(regulations for biogeneric products) | Business | Carole S. Ben-Maimon, Rob Garnick | |||
| Biopharmaceutical benchmarks 2006. | Business | Gary Walsh | |||
| BIO reaches adolescence.(James Greenwood appointed at Biotechnology Industry Organization) | Business | Jeffrey I. Fox | |||
| Biotech jostles with pharma for slice of HIV market. | Business | Alla Katsnelson | |||
| Biotech patents and the inequitable conduct doctrine. | Business | Anthony Michael | |||
| Biotech patents: Looking backward while moving forward.(Laboratory Corporation v. Metabolite Laboratories)(Laboratory Corporation of America Holdings) | Business | Rebecca S. Eisenberg | |||
| Biotech takes aim at large anti-estrogen markets. | Business | Mark Hollmer | |||
| Blue fluorescent proteins with enhanced brightness and photostability from a structurally targeted library. | Business | Thomas P. Treynor, Patrick S. Daugherty, Marco A. Mena, Stephen L. Mayo | |||
| Blueprint of an oil-eating bacterium. | Business | Victor de Lorenzo | |||
| BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm. | Business | David A. Shafritz, Gordon Keller, Atsushi Kubo, Valerie Gouon-Evans, Lise Boussemart, Paul Gadue, Christoph I. Koehler | |||
| Brazil and Japan give fuel to ethanol market. | Business | Ricardo Bonalume Neto, Claudia Orellana | |||
| Brazil next biotech trailblazer in Latin America? | Business | Ricardo Bonalume | |||
| Breeding new life into plant metabolism. | Business | James J. Giovannoni | |||
| Building manufacturing capacity - the chapter and verse. | Business | Michael E. Kamarck | |||
| Building nanoliteracy in the university and beyond. | Business | Chris Toumey, David Baird | |||
| Building the Midwest's future. | Business | Paul Smaglik | |||
| Can biofuels finally take center stage? | Business | Charlotte Schubert | |||
| Cancer biomarkers: A systems approach. | Business | Elizabeth Swisher, Lee Hartwell, David Mankoff, Amanda Paulovich, Scott Ramsey | |||
| Can Europe accelerate out of trouble. | Business | ||||
| Can science resolve the ethical impasse in stem cell research? | Business | Evan Y. Snyder, Lawrance M. Hinman, Michael W. Kalichman | |||
| CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. | Business | Jonathan M. Auerbach, Benjamin E. Reubinoff, Linh Nguyen, Martin F. Pera, Daniella Herszfeld, Ernst Wolvetang, Emma Langton-Bunker, Tung-Liang Chung, Adam A. Filipczyk, Souheir Houssami, Pegah Jamshidi, Karen Koh, Andrew L. Laslett, Anna Michalska, Irene Tellis, Carol J. Ording, Leendert H.J. Looijenga | |||
| Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. | Business | Eli Gilboa, Yong Wang, Paloma H. Giangrande, Bruce A. Sullenger, James O. McNamara II, Eran R. Andrechek, Kristi D. Viles, Rachel E. Rempel | |||
| Challenges in deriving high-confidence protein identifications from data gathered by HUPO plasma proteome collaborative study.(Human Proteome Organization) | Business | Gilbert S. Omenn, Jimmy Eng, David J. States, Thomas W. Blackwell, Damian Fermin, David W. Speicher, Samir M. Hanash | |||
| Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. | Business | Manuel J. Rodriguez-Ortega, Marirosa Mora, Tiziana Maggi, Nathaline Norais, Maria Scarselli, Anita Meumann, Giuliano Bensi, Francesco Doro, Alessia Covre, Sabrina Liberatori, Germano Ferrari, John L. Telford, Sabrina Capo, Ignazio Garaguso, Guido Grandi | |||
| Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential. | Business | Chien-Jung Huang, Alec Harootunian, Michael P. Maher, Catherine Quan, Christopher D. Raj, Ken McCormack, Randal Numann, Paul A. Negulescu, Jesus E. Gonzalez | |||
| Chimeras in the crosshairs7. | Business | Christopher Thomas Scott | |||
| China offers alternative gateways for experimental drugs. | Business | Jim Kling, Hepeng Jia | |||
| Chinese biotech: The need for innovation and higher standards.(William Haseltine)(Speech) | Business | Grace H.W. Wong | |||
| Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. | Business | James H. Prescott, Sara Lipka, Samuel Baldwin, Norman F. Sheppard Jr., John M. Maloney, Jonathan Coppeta, Barry Yomtov, Mark A. Staples, John T. Santini Jr. | |||
| Clinical trial data: To disclose or not to disclose? | Business | Aaron Bouchie | |||
| Combinatorial engineering of intergenic regions in operons tunes expression of multiple genes. | Business | Jay D. Keasling, Christina D. Smolke, Brian F. Pfleger, Douglas J. Pitera | |||
| Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities. | Business | Martha L. Bulyk, Michael F. Berger, Anthony A. Philippakis, Aaron M. Qureshi, Fangxue S. He, Preston W. Estep III | |||
| Complementary therapies for inflammation. | Business | Yi Wang | |||
| Complete genome of the mutualistic, [N.sub.2]-fixing grass endophyte Azoarcus sp. Strain BH72. | Business | Alfred Puhler, Thomas Hurek, Barbara Reinhold-Hurek, Stefan Weidner, Susanne Schneiker, Daniela Bartels, Thomas Bekel, Alexander Goesmann, Burkhard Linke, Alice C. McHardy, Frank-Jorg Vorholter, Olaf Kaiser, Andrea Krause, Adarsh Ramakumar, Federico Battistoni, Jens Boch, Melanie Bohm, Frauke Friedrich, Lutz Krause, Abhijit Sarkar, Arshad Ali Syed, Rudolf Thauer | |||
| Complete genome sequence of the entomopathogenic and metabolically versatile soil bacterium Pseudomonas entomophila. | Business | Bruno Lemaitre, Jean Weissenbach, Claudine Medigue, Valerie Barbe, Patrick Wincker, Claire Jubin, Laurence Cattolico, David Vallenet, Beatrice Segurens, Nicolas Vodovar, Stephane Cruveiller, Zoe Rouy, Carlos Acosta, Frederic Boccard, Aurelie Lajus | |||
| Comprehensive metabolic profiling and phenotyping of interspecific introgression lines for tomato improvement. | Business | Joachim Kopka, Nicolas Shauer, Semel, Yaniv; Roessner, Amit Gur, Ilse Balbo, Fernando Carrari, Tzili Pleban, Alicia Perez-Melis, Claudia Bruendigam, Lothar Willitzer, Dani Zamir, Alisdair R. Fernie | |||
| Connecting genes, drugs and diseases. | Business | John N. Weinstein, Yves Pommier | |||
| Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. | Business | Edison T. Liu, Vinsensius B. Vega, Lance D. Miller, Siew Hong Lam, Yan Tong, Huiqing Zhan, Kunde R. Govindarajan, Serene Lee, Sinnakarupan Mathavan, Karuturi R. Krishna Murthy, Donald R. Buhler, Zhiyuan Gong, Jan Spitsbergen | |||
| Convergence in biomedical technology. | Business | Robert Langer, Ascher Shmulewitz, John Patton | |||
| Counterpoint: Biotech needs more than DTC as usual.(direct-to-consumer) | Business | John Mack | |||
| Creation and implications of a phenome-genome network. | Business | Atul J. Butte, Isaac S. Kohane | |||
| Crystal gazing: Biotech's financial outlook. | Business | Eric Schmidt, David J. Strupp | |||
| Danish biotech outperforms its European counterparts. | Business | Nuala Moran | |||
| Data quality in genomics and microarrays. | Business | Ronald W. Davis, Hanlee Ji | |||
| Deciphering bioplastic production. | Business | Sang Yup Lee | |||
| Derivation of human embryonic stem cells in defined conditions. | Business | James A. Thomson, Tenneille E. Ludwig, Leann J. Crandall, Mark E. Levenstein, Christine A. daigh, W.Travis Berggren, Kevin R. Conard, Erika R. Mitchen, Piekarczyl S., Jennifer L. Frane, Llanas. Rachel A. | |||
| Designer combination therapy for cancer. | Business | David Lane | |||
| Determining the meaning of claim terms. | Business | Henry E. Auer | |||
| Deviant effects in molecular reaction pathways. | Business | Adam P. Arkin, Michael S. Samoilov | |||
| Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. | Business | David V. Schaffer, narandra Maheshri, James T. Koerber, Brian K. Kaspar | |||
| Doing business with the NIH.(National Institutes of Health) | Business | Gil Ben-Menachem, Steven M. Ferguson, Krishna Balakrishnan | |||
| Do targets limit antibiotic discovery? | Business | Molly B. Schmid | |||
| Drugging the P13 kinome.(treatment of malignant brain tumors ) | Business | Sandrine Guillard, Paul Workman, Paul A. Clarke, Florence I. Raynaud | |||
| Dual selection enhances the signaling specificity of a variant of the quorum-sensing transcriptional activator LuxR. | Business | Jared R. Leadbetter, Frances H. Arnold, Cynthia H. Collins | |||
| Early-stage returns?(life science technological firms) | Business | Bruce L. Booth | |||
| Efficient enucleation of erythroblasts differentiated in vitro from hematopoietic stem and progenitor cells. | Business | Yukio Nakamura, Kenichi Miharada, Takashi Hiroyama, Kazuhiro Sudo, Toshiro Nagasawa | |||
| Elliot Entis.(CEO and cofounder of Aqua Bounty Technologies) | Business | Kendal Powell | |||
| Emerging patent issues in genomic diagnostics. | Business | John H. Barton | |||
| Empowering microarrays in the regulatory setting. | Business | Janet Woodcock, Daniel A. Casciano | |||
| Endless possibilitie.(technologies used for biotech research) | Business | ||||
| Engineered membrane super channel improves bioremediation potential of dioxin-degrading bacteria. | Business | Wataru Hashimoto, Kousaku Murata, Bunzo Mikami, Yuji Aso, Yukiko Miyamoto, Karen Mine Hrada, Keiko Momma, Bunzo Kawai | |||
| Engineering and characterization of a superfolder green fluorescent protein. | Business | Geoffrey S. Waldo, Thomas C. Terwilliger, Jean-Denis Pedelacq, Timothy Tran | |||
| Engineering of a monomeric green-to-red photoactivatable fluorescent protein induced by blue light. | Business | Vladislav V. Verkhusha, Konstantin A. Lukyanov, Dmitry B. Staroverov, Sergey Lukyanov, Nadya G. Gurskaya, Alexander S. Shcheglov, Tatyana V. Chepurnykh, Arkady F. Fradkov | |||
| Engineering the essence of plants. | Business | Harro J. Bouwmeester | |||
| Erect leaves caused by brassinosteroid deficiency increase biomass production and grain yield in rice. | Business | Hiroshi Tanaka, Suguru Takatsuto, Shigeo Yoshida, Tomoaki Sakamoto, Miyako Ueguchi-Tanaka, Makoto Matsuoka, Hidemi Kitano, Kanzo Sakata, Masaharu Mizutani, Yoichi Morinaka, Toshiyuki Ohnishi, Hidehiko Sunohara, Shoza Fujioka | |||
| Ethical decision-making in bioscience firms. | Business | David Finegold, Allison Moser | |||
| Evaluation of DNA microarray results with quantitative gene expression platforms. | Business | Lu Zhang, Roger D. Canales, Yuling Luo, James C. Willey, Bradley Austermiller, Catalin C. Barbacioru, Cecilie Boysen, Kathryn Hunkapiller, Roderick V. Jensen, Charles R. Knight, Kathleen Y. Lee, Yunqing Ma, Botoul Maqsodi, Adam apallo, Elizabeth Herness Peters, Karen Poulter, Patricia L. Ruppel, Raymond R. Samaha, Shi Leming, Wen Yang, Federico M. Goodsaid | |||
| Evaluation of external RNA controls for the assessment of microarray performance. | Business | Lei Guo, Janet A. Warrington, Patrick J. Collins, Richard Shippy, Xu Guo, Yongming Andrew Sun, Leming Shi, Weida Tong, Xiaohui Fan, Hong Fang, Huixiao Hong, Michael S. Orr, Tzu-Ming Chu, Sue-Jane Wang, Wenjun Bao, Russell D. Wolfinger, Svetlana Shchegrova | |||
| Evidence and anecdotes: An analysis of human gene patenting controversies. | Business | John P. Walsh, Robert M. Cook-Deegan, Timothy Caulfield, F Scott Kieff | |||
| Executive compensation at private biotech companies: Beyond hearsay. | Business | Bruce Rychlik, Mike DiPierro | |||
| Exit strategies in Europe.(biotechnology companies)(Discussion) | Business | Peter Buckel, Ulrich Dauer | |||
| Expression of artificial microRNAs in transgenic Arabidopsis thaliana confers virus resistance. | Business | Nam-Hai Chua, Qi-Wen Niu, Shih-Shun Lin, Jose Luis Reyes, Kuan-Chun Chen, Shyi-Dong Yeh, Hui-Wen Wu | |||
| Extracellular accumulation of recombinant proteins fused to the carrier protein YebF in Escherichia coli. | Business | Guijin Zhang, Stephen Brokx, Joel H. Weiner | |||
| Fancy footwork in the sequence space shuffle. | Business | Frances H. Arnold | |||
| Fates intertwined.(future of biotechnology and pharmaceuticals) | Business | Garth J.S. Cooper | |||
| Finding the moral high ground.(ethical problems associated with the production of drugs) | Business | Ken Wilan | |||
| First-in-class cancer therapeutic to stimulate natural killer cells. | Business | Corm Sheridan | |||
| First inhalable insulin approved.(Exubera developed by Nektar Therapeutics) | Business | Alla Katsnelson | |||
| Fishing for cancer models. | Business | A. Thomas Look, Clemens Grabher | |||
| From oligos to Oprah - the consumer and biotech. | Business | John Mack, Paul Oestreicher, Tim Warner | |||
| Functional photoacoustic microscopy for high-resolution and noninvasive in vivo imaging. | Business | Hao F. Zhang, Konstantin Maslov, George Stoica, Lihong V. Wang | |||
| Gene prioritization through genomic data fusion. | Business | Peter Carmeliet, Peter Marynen, Diether Lambrechts, Sunit Maity, Bart De Moor, Stein Aerts, Van Loo Peter, Bert Coessens, Frederik De Smet, Leon-Charles Tranchevent, Bassem Hassan, Yves Moreau | |||
| Generation of cloned transgenic pigs rich in omega-3 fatty acids. | Business | Yifan Dai, Thomas E. Starzl, Liangxue Lai, Jing X. Kang, Rongfeng Li, Jingdong Wang, William T. Witt, Hwan Yul Yong, Yanhong Hao, David M. Wax, Clifton N. Murphy, August Rieke, Melissa Samuel, Michael L. Linville, Scott W. Korte, Rhobert W. Evans, Randall S. Prather | |||
| Gene targeting in vivo by adeno-associated virus vectors. | Business | Daniel G. Miller, David W. Russell, Mark S. Sands, Pei-Rong Wang, Lisa M. Petek, Roli K. Hirata | |||
| Genetic profiteering.(genetic tests for diagnosing cancer) | Business | Laura De Francesco | |||
| Genome sequence of the bioplastic-producing "Knallgas" bacterium Ralstonia eutropha H16. | Business | Alexander Steinbuchel, Gerhard Gottschalk, Markus Potter, Heiko Liesegang, Wolfgang Florian Fricke, Anne Pohlmann, Edward Schwartz, Axel Strittmatter, Ingo VoB, Frank Reinecke, Christian Ewering, Bernhard Kusian, Thomas Eitinger, Rainer Cramm, Barbel Friedrich, Botho Bowien | |||
| Genome sequence of the ubiquitous hydrocarbon-degrading marine bacterium Alcanivorax borkumensis. | Business | Alfred Puhler, Kenneth N. Timmis, Manuel Ferrer, Tatyana N. Chernikova, Peter N. Golyshin, Jens Buhrmester, Stefan Weidner, Michail M. Yakimov, Folker Meyer, Susanne Schneiker, Vitor A.P. Martins dos Santos, Daniela Bartels, Thomas Bekel, Martina Brecht, Renata Denaro, Alexander Goesmann, Olga V. Golyshina, Christoph Gertler, Filip Kaminski, Amit N. Khachane, Siegmund Lang, Burkhard Linke, Alice C. McHardy, Taras Nechitaylo, Daniela Regenhardt, Oliver Rupp, Julia S. Sabirova, Werner Selbitschka, Frank-Jorg Vorholter, Olaf Kaiser | |||
| Getting it right the first time. | Business | Barbara M. Johnson | |||
| Global mapping of pharmacological space. | Business | Gaia V. Paolini, Richard H.B. Shapland, Willem P. van Hoorn, Jonathan S. Mason, Andrew L. Hopkins | |||
| Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. | Business | Pina M. Cardarelli, Severino Cuison, Mohan Srinivasan, Kevin M. Cox, Jason D. Sterling, Jeffrey T. Regan, John R. Gasdaska, Karen K. Frantz, Charles G. Peele, Amelia Black, David Passmore, Cristina Moldovan-Loomis, Lynn F. Dickey | |||
| Gold in the ivory tower: Equity rewards of outlicensing. | Business | Mark Edwards, Fiona Murray, Robert Yu | |||
| Ground control for insect pests. | Business | Richard H. French-Constant, Nicholas R. Waterfield | |||
| Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. | Business | Luigi Naldini, Manfred Schmidt, Cynthia Bartholomae, Lucia Sergi Sergi, Eugenio Montini, Daniela Cesana, Franseca Sanvito, Maurilio Ponzoni, Alessandro Ambrosi, Clelia Di Serio, Claudio Doglioni, von Kalle Christof | |||
| Herbicide-resistance conferred by expression of a catalytic antibody in Arabidopsis thaliana. | Business | Yael Weiss, Avidor Shulman, Irina Ben Shir, Ehud Keinan, Shmuel Wolf | |||
| High-resolution computational models of genome binding events. | Business | Richard A. Young, Julia Zeitlinger, David K. Gifford, Tommi S. Jaakkola, Ernest Fraenkel, Yuan Qi, Alex Rolfe, Kenzie D. Macisaac, Gerog K. Gerber, Dmitry Pokholok, Timothy Danford, Robin D. Dowell | |||
| How does DNA sequence motif discovery work? | Business | Patrik D'haeseleer | |||
| Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. | Business | Charles R. Mackay, Fabienne Mackay, Hyun Lee, Frank Koentgen, David Zahra, Soren B. Padkjaer, Peter L. Whitfield, Alexis Vogelzang, Jorg Zwirner, Rebecca Newton, Trina So, Jenny Thatcher, Annie Quan | |||
| IBM opens the IP vaults.(International Business Machines Corp.)(intellectual property) | Business | George S. Mack | |||
| Identification and immunotherapeutic targeting of antigens induced by chemotherapy. | Business | Paul Polakis, Bonnee Rubinfeld, hartmut Koeppen, Archana Upadhyay, Sarajane Ross, Suzanna L. Clark, Sharon E. Fong, Victoria Smith | |||
| Impact of microarray data quality on genomic data submissions to the FDA. | Business | Felix W. Frueh | |||
| Implementing biofuels on a global scale. | Business | Masayuki Inui, Hideaki Yukawa, Alain A. Vertes | |||
| Induced pluripotency and cellular alchemy. | Business | Anthony C. F. Perry | |||
| Industry warily eyes new Medicare drug plan. | Business | Nuala Moran | |||
| Inference in Bayesisan networks. | Business | Chris J. Needham, James R. Bradford, Andrew J. Bulpitt, David R. Westhead | |||
| Insights into US public biotech sector using patenting trends. | Business | Sharmistha Bagchi-Sen, Saurabh Aggarwal, Vinay Gupta | |||
| In silico pharmacogenetics of warfarin metabolism. | Business | Paul Weller, Yingying Guo, Erin Farrell, Gary Peltz, Paul Cheung, Bill Fitch, Douglas Clark, Mohammad Masjedizadeh, Shao-yong Wu, Jianmei Wang, Guochun Liao, Zhaomei Zhang, John Allard, Janet Cheng, Anh Nguyen, Jiang Sharon, Steve Shafer, Jonathan Usuka | |||
| Investing in green and white biotech.(biomass energy investments) | Business | Michael W. Bevan, Maurice C.R. Franssen | |||
| Ion-channel drug screening galvanized. | Business | Paul B. Bennet | |||
| Israeli biotech comes into its own.(Rebif, Copaxaone, Exelon and Doxil are best selling medicines) | Business | Bernard Dichek | |||
| Keeping it real with investors.(investment in biotech products) | Business | James Baker, Charles Harris, Tim Harper, Michelle Dipp, Christopher Westphal, Chad Mirkin | |||
| Know the enemy.(prevention of avian influenza) | Business | Ee Chee Ren | |||
| Lack of private financing hobbles emerging biotech regions. | Business | Hepeng Jia, Jayarama, Marina Astvatsaturyan | |||
| Liberty link rice raises specter of tightened regulations. | Business | Peter Vermij | |||
| Making the most of microarrays. | Business | ||||
| Merck wipes Serono off Swiss biotech map. | Business | Lisa Urquhart | |||
| Metagenomic analysis of two enhanced biological phosphorus removal (EBPR) sludge communities. | Business | Philip Hugenholtz, Christine Yeates, Falk Warnecke, Eileen Dalin, Kerrie W. Barry, Natalia Ivanova, Alice C. McHardy, Isidore Rigoutsos, Hector Garcia Martin, Ernest Szeto, Asaf A. Salamov, Nik H. Putnam, Victor Kunin, Shaomei He, Harris J. Shapiro, Katherine D. McMahon, Jasmyn L. Pangilinan, Linda Louise Blackall, Nikos C. Kyrpides | |||
| Michael Fernandez.(Pew Initiative on Food and Biotechnology) | Business | Kendall Powell | |||
| Missing: Entrepreneurial women in biotech. | Business | Crispin Littlehales | |||
| Modeling cellular machinery through biological network comparison. | Business | Trey Ideker, Roded Sharan | |||
| Molecular engineering approaches to peptide, polyketide and other antibiotics. | Business | Richard H. Baltz | |||
| Monoclonal expand into neural disorders. | Business | Brian Vastang | |||
| Moving goalposts-regulatory oversight of antibacterial drugs. | Business | Randall Brenner, Evelyn J. Ellis-Grosse, Roger Echols | |||
| My worst biotech investment.(Visudyne of QLT Phototherapeutics Inc.) | Business | Tom Jacob | |||
| Nanomedicine lacks recognition in Europe. | Business | Nuala Maron | |||
| Nature biotechnology: Lost in validation.(trend of developing biological markers) | Business | ||||
| Navigating the future(s) of biotech intellectual property. | Business | Kenneth Neil Cukier | |||
| Neurotrophins mediate human embryonic stem cell survival. | Business | Peter J. Donovan, April D. Pyle, Leslie F. Lock | |||
| New antibiotics from bacterial natural products. | Business | Jon Clardy, Christopher T. Walsh, Michael A. Fischbach | |||
| New 'omics tools for fission yeast. | Business | Shelley Sazer | |||
| No longer lost in translation. | Business | Yale E. Goldman, Barry S. Cooperman | |||
| Not for the chicken-hearted. | Business | ||||
| Nuclear transfer saddles up. | Business | Stephaine L. Church | |||
| Off the beaten path.(prospects of biotechnology industry) | Business | Sabine Louet, Mark Wilson, Halla Thorsteinsdottir, Alok Gupta, Jonathan Buckley, Jorge Gatica, Mark Tang, Min-Chol Shin | |||
| Open software for biologists: From famine to feast. | Business | Dawn Field, Bela Tiwari, Tim Booth, Stewart Houten, Dan Swan, Nicolas Bertrand, Milo Thurston | |||
| Optimization of humanized IgGs in glycoengineered Pichia pastoris. | Business | Sandra Rios, Huijuan Li, Nicole Ballew, Nga Rewa Houston-Cummings, Youwei Jiang, Natarajan Sethuraman, Piotr Bobrowicz, Robert davidson, Nam Kim, Terrance A. Stadheim, Byung-Kwon Choi, Bing Gong, Renee Mansfield, Dongxing Zha, W.James Cook, Stephen R. Hamilton, Juergen H. Nett, Bianka Prinz, Rendall Strawbridge, Stefan Wildt, Tillman Gerngross, Michael Cukan, Jack P. Hoopes | |||
| Ordered surface carbons distinguish antifreeze proteins and their ice-binding regions. | Business | Andrew C. Doxey, Mahmoud W. Yaish, Marilyn Griffith, Brendan J. McConkey | |||
| ORFeome cloning and global analysis of protein localization in the fission yeast Schizosaccharomyces pombe. | Business | Sueharu Horinouchi, Yasushi Hiraoka, Akihisa Matsuyama, Ritsuko Arai, Yoko Yashiroda, Atsuko Shirai, Ayako Kamata, Shigeko Sekido, Yumiko Kobayashi, Atushi Hashimoto, Makiko Hamamoto, Minoru Yoshida | |||
| Oversight of US genetic testing laboratories. | Business | Joan Scott, Kathy L. Hudson, Juli A. Murphy, David J. Kaufman, Gail H. Javitt, Sara H. Katsanis | |||
| Parallel universes? An EU Commissioner has a meeting of minds with an antibiotech agitator.(Editorial) | Business | ||||
| Partnering for better microbial diagnostics. | Business | Peter M. Small, Mark D. Perkins | |||
| Partnering with a difference.(EuroBio 2006)(Editorial) | Business | ||||
| Partnerships in African crop biotech. | Business | Joanna Chataway, Seife Ayele, David Weild | |||
| Patenting race.(biotechnology research) | Business | Jonathan Kahn | |||
| Patently absurd?(patent infringement) | Business | Ken Garber, Ann Arbor | |||
| Patently transparent. | Business | ||||
| Pension plans dally with biotech. | Business | John Ransoms | |||
| Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. | Business | Liang Zhang, Patrick J. Collins, Leming Shi, Weida Tong, Hong Fang, Tzu-Ming Chu, Wenjun Bao, Russell D. Wolfinger, Tucker A. Patterson, Edward K. Lobenhofer, Stephanie B. Fulmer-Smentek, Ernest S. Kawasaki, Janet Hager, Irina R. Tikhonova, Stephen J. Walker, Patrick Hurban, Francoise de Longueville, James C. Fuscoe | |||
| Phage display extends its reach. | Business | Damon Huber | |||
| Plants tackle explosive contamination. | Business | Richard B. Meagher | |||
| Post-translational modifications in the context of therapeutic proteins. | Business | Gary Walsh, Roy Jefferis | |||
| Power dating: A guide to VC courtship.(venture capital) | Business | Karen Boezi, Elliot Parks, Laura Shawver, Scott Salka, Chris Ehrlich | |||
| Preventing gene silencing with human replicators. | Business | Lixin Wang, Eric E. Bouhassira, Haiqing Fu, Chii-Mei Lin, Sumegha Singhania, Mirit I. Aladjem | |||
| Private biotech 2004- the numbers. | Business | John Hodgson | |||
| Production of a recombinant bacterial lipoprotein in higher plant chloroplasts. | Business | Karin Glenz, Heribert Warzecha, Bernadette Bouchon, Thomas Stehle, Reinhard Wallich, Markus M. Simon | |||
| Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. | Business | Anne G. Bang, Melissa K. Carpenter, Evert Kroon, Kevin A. D'Amour, Alan D. Agulnick, Susan Eliazer, Olivia G. Kelly, Emmanuel E. Baetge, Nora G. Smart, Mark A. Moorman | |||
| Profile of a bacterial tumor killer. | Business | Neil S. Forbes | |||
| Prospects for plant-derived antibacterials. | Business | Kim Lewis, Frederick M. Ausubel | |||
| Protein biomarker discovery and validation: The long and uncertain path to clinical utility. | Business | Nader Rifai, Steven A. Carr, Michael A. Gillette | |||
| Protein chip fabrication by capture of nascent polypeptides. | Business | Heng Zhu, Sheng-Ce Tao | |||
| Public biotechnology 2005- the numbers. | Business | Riku Lahteenmaki, Stacy Lawrence | |||
| Putting immunoinformatics to the test. | Business | Leonard Moise, Anne S. De Groot | |||
| Putting pharmacogenetics into practice. | Business | Paul Nightingale, Jim Ryan, Dolores Ibarreta, Micheal M. Hopkins, Sibylle Gaisser, Christien M. Enzing, Paul A. Martin, Graham Lewis, Symone Detmar, M. Elske van den Akker-van Marle, Adam M. Hedgecoe, Marieke Dreiling, K. Juliane Hartig, Wieneke Vullings, Tony Forde | |||
| Putting proteins on the map.(subcellular protein location ) | Business | Robert F. Murphy | |||
| Rainbow biotech-South Africa's emerging sector. | Business | Sabine Louet | |||
| Rat toxicogenomic study reveals analytical consistency across microarray platforms. | Business | Lei Guo, Lu Zhang, Jun Xu, Tao Chen, Stephen C. Harris, Federico M. Goodsaid, Richard Shippy, Yongming Andrew Sun, Leming Shi, Damir Herman, Weida Tong, Edward K. Lobenhofer, Patrick Hurban, Charles Wang, Nan Mei, Kenneth L. Phillips, Xutao Deng, Yvonne P. Dragan | |||
| Recombinant expression of selectivity sulfated proteins in Escherichia coli. | Business | Peter G. Schultz, Chang C. Liu | |||
| Redirection of cytosolic or plastidic isoprenoid precursors elevates terpene production in plants. | Business | Shuiqin Wu, Michel Schalk, Anthony Clark, Brandon R. Miles, Robert Coates, Joe Chappell | |||
| Reinventing phage therapy: Are the parts greater than the sum? | Business | Vincent A. Fischetti, Daniel Nelson, Raymond Schuch | |||
| Replicators lessen transcriptional silencing. | Business | Carl L. Schildkraut, Zeqiang Guan | |||
| Research policy and the mobility of US stem cell scientists. | Business | Aaron D. Levine | |||
| Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. | Business | Hirofumi Noguchi, Teru Okitsu, Yong Chen, Michiki Narushima, Naoya Kobayashi, Jorge David Rivas-Carrillo, Kimiaki Tanaka, Nalu Navarro-Alvarez, Atsushi Miki, Hee-Sook Jun, Noriaki Tanaka, Alejandro Soto-Gutierrez, Debaio Zhao, Hesham Basma, Yashuhiko Tabata, Tadayoshi Ueda, Ji-Won Yoon, Jane Lebkowski, Ira J. Fox | |||
| Riboswitches as antibacterial drug targets. | Business | Ronald R. Breaker, Kenneth F. Blount | |||
| RISC control for gene therapy. | Business | Adrian J. Thrasher, Waseem Qasim | |||
| RNAi in moderation. | Business | Sailen Barik | |||
| RNA interference below the immune radar. | Business | Mouldy Sioud | |||
| RNAi tackles a sexually transmitted disease. | Business | Bharat Ramratnam, Patricia Cristofaro | |||
| RNA synthetic biology. | Business | James J. Collins, Daniel J. Dwyer, Farren J. Isaacs | |||
| Screening for peptide drug from the natural repertoire of biodiverse protein folds. | Business | Paul M. Watt | |||
| Self-illuminating quantum conjugates for in vivo imaging. | Business | Min-Kyung So, Chenjie Xu, Andreas M. Loening, Sanjiv S. Ghambhir, Jianghong Rao | |||
| Self-illuminating quantum dots light the way. | Business | John V. Frangioni | |||
| Sequencing genomes from single cells by polymerase cloning. | Business | Sallie W. Chisholm, George M. Church, Adam C. Martiny, Nikos B. Reppas, Kun Zhang, Kerrie W. Barry, Joel Malek | |||
| Shifting emphasis from pharmacogenomics to theragnostics. | Business | Ming T. Tsuang, James B. Lohr, Christopher Reist, Stephen J. Glatt, Vural Ozdemir, Bryn Williams-Jones | |||
| Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. | Business | Shuanglin Xiang, Johannes Fruehauf, Chiang J. Li | |||
| Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. | Business | Andreas Pluckthun, Michael T. Stumpp, Patrik Forrer, Daniel Steiner | |||
| Single-cell genomics. | Business | J. Craig Venter, Clyde A. Hutchison III | |||
| Small company mergers-good for whom? | Business | William Bains, Vanessa Maybeck | |||
| South Korean policy failure and the Hwang debacle.(Roh Moo-Hyun) | Business | Robert Triendl, Herbert Gottweis | |||
| Specificity by design.(alteration of endonuclease by using gene cloning) | Business | Carl O. Pabo | |||
| Stable expression of shRNAs in human CD34(super +) progenitor cells can avoid induction of interferon responses to siRNAs in vitro. | Business | John J. Rossi, Mark A. Behlke, Marjorie A. Robbins, Mingjie Li, Irene Leung, Haitang Li, Doris V. Boyer, Yong Song | |||
| Standard operating procedures. | Business | ||||
| Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins. | Business | Ravi S. Kane, Jeremy Mogridge, Prakash Rai, Chakradhar Padala, Vincent Poon, Arundhati Saraph, Saleem Basha, Sandesh Kate, Kevin Tao | |||
| Statistical practice in high-throughput screening data analysis. | Business | Robert Nadon, Jerry Pelletier, James A. Hanley, Nathaline Malo, Sonia Cerquozzi | |||
| Stem cell-derived erythroid cells mediate long-term systemic protein delivery. | Business | Michel Sadelain, Alex H. Chang, Matthias T. Stephan | |||
| Steroid regulation improves crop yield. | Business | Kenneth A. Feldmann | |||
| Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. | Business | Roger G. Fahmy, Colin N. Chesterman, Levon M. Khachigian, Alla Waldman, Guishui Zhang, Ainslie Mitchell, Nicodemus Tedla, Hong Cai, Carolyn R. Geczy, Michael Perry | |||
| Systems biology, incorporated? | Business | Karl Thiel | |||
| Ten years of biotech gaffes.(past ten years of biotechnology industry)(Industry overview) | Business | John Hodgson | |||
| The art of mismanagement.(ImClone Systems Inc.) | Business | ||||
| The biotech company view.(Industry overview) | Business | Roger Echols | |||
| The breeder's dilemma-yield or nutrition? | Business | David C. Sands, Cindy E. Morris | |||
| The business of developing antibacterials. | Business | Jeffrey L. Fox | |||
| The CREATE Act: Increasing costs associated with the biotech industry?(Cooperative Research and Technology Enhancement Act of 2004) | Business | Ann E. Mills, Donna T. Chen, John J. Gillon Jr., Patti M. Tereskerz | |||
| The emerging nanomedicine landscape.(nanomedicine market)(Industry overview) | Business | Volker Wagner, Anwyn Dullaart, Anne-Katrin Bock, Axel Zweck | |||
| The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. | Business | Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Xin Huang, Luis A. Diaz Jr., Giovanni Parmigiani, Chetan Bettegowda, Jimmy Lin, Ian Cheong, Manu Kohli, Stephen A. Szabo, Xiaosong Zhang, Shibin Zhou | |||
| The germ of pluripotency. | Business | Mito Kanatsu-Shinohara, Takashi Shinohara | |||
| The hardest hire: Today's chief medical officer. | Business | Mari Paul | |||
| The hermit crab solution.(mergers and public offerings in biotech companies) | Business | Elizabeth Silverman | |||
| The human use of humanoid beings: Chimeras and patent law. | Business | Sander Rabin | |||
| The imitation game: a computational chemical approach to recognizing life. | Business | Andrei N. Khlobystov, Leroy Cronin, Paul M. Gardner, Peter Siepmann, Natalio Krasnogor, Geoff Cooper, Benjamin J. Whitaker, Benjamin G. Davis, Dan Marsh, Cameron Alexander, Sven L.M. Schroeder, Neil Robertson, Joachim H.G. Steinke | |||
| The importance of getting inventorship right.(patent licensing for inventors and not companies) | Business | Diana Sheiness, Karen Canady | |||
| The investment banker's view. | Business | David J. Strupp Jr. | |||
| The licensing of DNA patents by US academic institutions: An empirical survey. | Business | Robert M. Cook-Deegan, Lori Pressman, Melissa Soucy, LeRoy Walters, Richard Burgess, Stephen J. McCormack, Io Naomi-Wolk | |||
| The medium is the message.(human embryonic stem) | Business | Harry Moore | |||
| The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. | Business | ||||
| The need for standards, not guidelines, in biological data reporting and sharing. | Business | Lyle D. Burgoon | |||
| The next chapter in reverse vaccinology.(method to develop vaccine) | Business | James M. Musser | |||
| The next generation?(biotechnology industry) | Business | ||||
| The patentability of human embryonic stem cells in Europe. | Business | Gerard Porter, Chris Denning, Aurora Plomer, John Sinden, Paul Torremans | |||
| The paths around stem cell intellectual property. | Business | Christopher Thomas Scott, Henry T. Greely, Kenneth S. Taymor | |||
| The promise of the East: India and China as R&D options. | Business | Simon Goodall, Bart Janssens, Kim Wagner, John Wong, Wendy Woods, Michael Yeh | |||
| The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. | Business | Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein | |||
| The second wave in kinase cancer drugs.(Onyx Pharmaceuticals Inc.) | Business | Ken Garber | |||
| The selfish stem cell. | Business | Peter W. Andrews | |||
| The sweet side of biomarker discovery. | Business | Ram Sasisekharan, Carlos J. Bosques, S. Raguram | |||
| The worm turns for antimicrobial discovery. | Business | Amit P. Bhavsar, Eric D. Brown | |||
| Thinking outside the cell. | Business | Corie Lok | |||
| Three barriers to innovative diagnostics. | Business | Paul R. Billings | |||
| Towards cell therapy for diabetes. | Business | Palle Serup, Ole D. Madsen | |||
| Transdermal protein delivery by a coadministered peptide identified via phase display. | Business | Yongping Chen, Yuanyuan Shen, Xin Guo, Caoshou Zhang, Wenjuan Yang, Minglu Ma, Shu Liu, Maobin Zhang, Long-Ping Wen | |||
| Transgenesis sunny-side up. | Business | Helen Sang | |||
| Transgenic crops expressing Bacillus thuringiensis toxins and biological control. | Business | ||||
| Translating in vivo diagnostics into clinical reality.(Food and Drug Administration) | Business | John V. Frangioni | |||
| Transposon-free insertions for insect genetic engineering. | Business | George C. Condon, Neil I. Morrison, Luke Alphey, Tarig H. Dafa'alla, Kirsty C. Condon, Caroline E. Phillips, Mathew J. Epton, Guoliang Fu | |||
| Trendspotting: A shift in intellectual property focus. | Business | Marcia H. Anderegg, Joshua M. Thayer, Kathleen M. Williams | |||
| Trendspotting: Betting strong but playing safe.(life science companies) | Business | Marcia H. Anderegg, Joshua M. Thayer, Kathleen M. Williams | |||
| Trust, patents and public perceptions: the governance of controversial biotechnology research. | Business | Jon F. Merz, Timothy Caulfield, Edna Einsiedel, Dianne Nicol | |||
| Turning plants into protein factories. | Business | Jeffrey L. Fox | |||
| Tyrosine sulfate trapped by amber. | Business | Michael Farzan, Hyeryun Choe | |||
| US-Indian agbiotech deal under scrutiny. | Business | K.S. Jayaraman | |||
| Using RNA sample titrations to assess microarray platform performance and normalization techniques. | Business | Janet A. Warrington, James C. Willey, Cecilie Boysen, Richard Shippy, Stephanie Fulmer-Smentek, Roderick V. ensen, Wendell D. Jones, Paul K. Wolber, Charles D. Johnson, P Scott Pine, Xu Guo, Eugene Chudin, Yongming Andrew Sun, Jean Thierry-Mieg, Danielle Thierry-Mieg, Robert A. Setterquist, Mike Wilson, Anne Bergstrom Lucas, Natalia Novoradovskaya, Adam Papallo, Turpaz Yaro, Shawn C. Baker, Leming Shi, Damir Herman | |||
| Vaccine manufacturing: Challenges and solutions. | Business | Rino Rappuoli, Jeffrey B. Ulmer, Ulrich Valley | |||
| Wastewater genomics.(enhanced biological phosphate removal) | Business | Takashi Mino, Hiroyasu Satoh | |||
| Welcome to the body-wide web.(online health information services ) | Business | David Shenk | |||
| What are DNA sequence motifs? | Business | Patrik D'haeseleer | |||
| What are you worth? | Business | Mary Yaroshevsky-Glanville | |||
| What brown cannot do for you. | Business | David L. Rimm | |||
| What is a support vector machine? | Business | William S. Noble | |||
| When the price is right. | Business | ||||
| Where have all the antibiotic patents gone? | Business | Martin L. Katz, Lisa V. Mueller, Mark Polyakov, Steven F. Weinstock | |||
| Where the money is. | Business | Michael Fitzgerald | |||
| Whither agbiotechnology?(future of agricultural biotechnology) | Business | L. Val Giddings | |||
| Who took the tech out of biotech? | Business | Elizabeth Silverman | |||
| Why media relations matter.(biotech industry faces competition) | Business | Joan E. Kureczka | |||
| Why silence is not an option.(genetically modified crops)(Editorial) | Business | ||||
| Why spurning food biotech has become a liability. | Business | Drew L. Kershen, Henry I Miller, Gregory Conko | |||
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.